Cantor Fitzgerald Reaffirms ‘Overweight’ Rating for ALX Oncology (NASDAQ:ALXO)

ALX Oncology (NASDAQ:ALXO – Get a Free Report)The stock’s “overweight” rating was reiterated by equities researchers at Cantor Fitzgerald in a research note on Monday, Benzinga reports.

Several other equities analysts have also commented on the stock. Lifesci Capital cut shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Stifel Nicolaus reissued a “hold” rating and issued a $3.00 price objective (down from $5.00) on shares of ALX Oncology in a report on Friday. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Moderate Buy” and a consensus price target of $17.83, according to MarketBeat.

See the latest stock analysis on ALXO

ALX Oncology stock fell 0.8%

Shares of ALXO stock opened at $2.61 on Monday. The company’s 50-day moving average price is $6.35 and its 200-day moving average price is $11.43. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.21, and a current ratio of 5.21. ALX Oncology has a fifty-two week low of $2.45 and a fifty-two week high of $17.83. The firm has a market cap of $135.98 million, a price-to-earnings ratio of -0.70 and a beta of 1.06.

ALX Oncology (NASDAQ:ALXO – Get Your Free Report ) last released its earnings results on Thursday, August 8th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.01. On average, equities research analysts anticipate that ALX Oncology will post -2.89 EPS for the current fiscal year.

Insider buying and selling

In related news, insider Jaume Pons sold 20,000 shares of the stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $8.43, for a total transaction of $168,600.00. Following the completion of the sale, the insider now directly owns 604,205 shares of the company’s stock, valued at $5,093,448.15. The sale was disclosed in a filing with the SEC, which is available on the SEC’s website. In related news, insider Jaume Pons sold 20,000 shares of the stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $8.43, for a total transaction of $168,600.00. Following the completion of the sale, the insider now directly owns 604,205 shares of the company’s stock, valued at $5,093,448.15. The sale was disclosed in a filing with the SEC, which is available on the SEC’s website. Also, CFO Peter S. Garcia purchased 12,000 shares of the business’s stock in a transaction dated Thursday, June 13th. The stock was purchased at an average price of $8.53 per share, with a total value of $102,360.00. Following the transaction, the chief financial officer now directly owns 122,348 shares of the company’s stock, valued at approximately $1,043,628.44. Disclosure for this purchase can be found here. Insiders have sold a total of 46,469 shares of company stock worth $363,666 over the past three months. 33.40% of the shares are currently owned by company insiders.

Institutional inputs and outputs

Hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of ALX Oncology in the fourth quarter valued at $28,000. CANADA LIFE ASSURANCE Co purchased a new position in shares of ALX Oncology in the first quarter valued at $27,000. EntryPoint Capital LLC purchased a new position in shares of ALX Oncology during the first quarter valued at $32,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of ALX Oncology by 66.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock valued at $107,000 after purchasing an additional 3,825 shares in the last quarter. Hedge funds and other institutional investors own 97.97% of the company’s shares.

ALX Oncology Company Profile

(Get a free report)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, is focused on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47-blocking biologic, being developed as a combination therapy with other anti-cancer agents, including ASPEN-06, in a Phase 2 clinical trial for the treatment of gastric/GEJ cancer; ASPEN-07, in the phase 1 clinical trial for the treatment of urothelial cancer; and ASPEN-03 and ASPEN-04, both in phase 2 clinical trials for the treatment of head and neck squamous cell carcinoma.

Featured stories

Get news and reviews for ALX Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ALX Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.